A detailed history of Perceptive Advisors LLC transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Perceptive Advisors LLC holds 1,105,341 shares of AXSM stock, worth $89 Million. This represents 1.85% of its overall portfolio holdings.

Number of Shares
1,105,341
Previous 1,038,019 6.49%
Holding current value
$89 Million
Previous $82.6 Million 6.77%
% of portfolio
1.85%
Previous 2.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$69.39 - $97.64 $4.67 Million - $6.57 Million
67,322 Added 6.49%
1,105,341 $88.2 Million
Q4 2023

Feb 14, 2024

BUY
$57.42 - $83.61 $31.9 Million - $46.5 Million
556,370 Added 115.51%
1,038,019 $82.6 Million
Q3 2023

Nov 14, 2023

BUY
$69.25 - $82.21 $14.6 Million - $17.3 Million
210,156 Added 77.41%
481,649 $33.7 Million
Q2 2023

Aug 14, 2023

BUY
$58.41 - $90.35 $15.9 Million - $24.5 Million
271,493 New
271,493 $19.5 Million
Q1 2022

May 16, 2022

SELL
$23.7 - $41.39 $1.91 Million - $3.33 Million
-80,420 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$19.91 - $68.26 $9.43 Million - $32.3 Million
-473,488 Reduced 85.48%
80,420 $2.65 Million
Q2 2021

Aug 16, 2021

BUY
$50.63 - $73.5 $28 Million - $40.7 Million
553,908 New
553,908 $37.4 Million
Q3 2020

Nov 16, 2020

SELL
$68.34 - $85.84 $3.42 Million - $4.29 Million
-50,000 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$49.87 - $98.69 $2.49 Million - $4.93 Million
50,000 New
50,000 $4.11 Million
Q4 2019

Feb 14, 2020

SELL
$16.71 - $106.24 $900,318 - $5.72 Million
-53,879 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$2.63 - $16.34 $141,701 - $880,382
53,879 New
53,879 $767,000

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $3.45B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Perceptive Advisors LLC Portfolio

Follow Perceptive Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.